A Multi-laboratory, Multi-country Study To Determine Bedaquiline And Delaminid Minimal Inhibitory Concentration Quality Control Ranges For Phenotypic Drug Susceptibility Testing
Collaborator: D Cirillo; San Rafelle Institute, Milan, Italy
Bedaquiline is a new diarylquinoline antimycobacterial drug, used in the treatment of MDR-TB. Delaminid is also a new agent and will likely become available in the near future for patient management. A series of laboratory investigations was initiated to establish standardised drugsusceptibility testing (DST) methodologies and reference minimal inhibitory concentration (MIC) QC ranges for this new anti-TB drug. Two tier-2 QC reproducibility studies of bedaquiline DST were conducted in eight geographically diverse laboratories, using Clinical Laboratory and Standards Institute (CLSI) guidelines.